The infusion rate should be reduced by 50% in case of nonserious infusion reactions In patients who develop serious infusion reactions, cetuximab should be discontinued immediately and permanently ...

The authors conclude that KRAS mutation status can be used to identify the subgroup of patients with irinotecan-refractory metastatic CRC who are most likely to respond to cetuximab.